Last reviewed · How we verify
Treatment Choice (TC)
Treatment Choice (TC) is a small molecule that targets the CD47/SIRPα axis.
Treatment Choice (TC) is a small molecule that targets the CD47/SIRPα axis. Used for Relapsed or refractory acute myeloid leukemia (AML).
At a glance
| Generic name | Treatment Choice (TC) |
|---|---|
| Sponsor | Astex Pharmaceuticals, Inc. |
| Drug class | SIRPα inhibitor |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TC works by blocking the interaction between CD47 and SIRPα on the surface of tumor cells, which can help the immune system recognize and attack cancer cells.
Approved indications
- Relapsed or refractory acute myeloid leukemia (AML)
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon） (PHASE3)
- Efficacy of Ra-223 in PSMA PET Optimally Selected Patients (PHASE2)
- To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors (PHASE2)
- Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer (NA)
- Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery: a Single Center Experience
- Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia (PHASE3)
- SGI-110 in Combination With Carboplatin in Ovarian Cancer (PHASE2)
- SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |